Sunday, June 28, 2026 Never be the last to know Go Pro · $20/mo →
Inside MedSpa
Intelligence for Medical-Aesthetics Owners
FDA CLEAREDIntense Pulsed Light Therapy Device — Sanhe LEFIS Electronics Co., Ltd.2 weeks agoFDA CLEAREDLASEmaR 1500 — Eufoton S.R.L.4 weeks agoFDA CLEAREDBarbed PDO Suture — Sutura Medical Technology, Inc.2 weeks agoFDA CLEAREDVeineo System (00MEDRF4000TCUS 05CR45iT 06Pedal1St) — F Care Systems USA, LLC4 weeks agoFDA CLEAREDERBECRYO 2 Cryosurgical Unit and Accessories — Erbe Elektromedizin GmbH3 weeks agoFDA CLEAREDMILAN System — Lumenis Be, Ltd.4 weeks agoFDA CLEAREDLipocosm Harmonic System — Lipocosm, LLC3 weeks agoFDA CLEAREDCurrentBody Skin LED Multi Light Therapy Mask (MK-110D) — The Beauty Tech Group, Ltd.4 weeks agoFDA CLEAREDLumiGlam Laser System (SHE-LSP601-3) — Beijing Sano Laser S&T Development Co.,Ltd3 weeks ago
1 free article left this week. A free account gets you 4 a week.Go Pro →
Business & M&A

Evolus Files Multiple Material Events — Jeuveau Competitive Moves Underway

Evolus's SEC filings suggest strategic shifts in Jeuveau pricing or Evolus Rewards loyalty program; price-war dynamics accelerating.

Photo: www.kaboompics.com · Pexels

Evolus has filed multiple material events with the SEC (March 13, May 4, and June 12, 2026), signaling potential strategic changes to Jeuveau pricing, market positioning, or the Evolus Rewards loyalty program structure. Evolus has historically marketed aggressively to independent medspas and practices seeking alternatives to AbbVie's Botox dominance, leveraging lower wholesale pricing and more flexible rebate terms as competitive levers.

Evolus's three material events in four months signal competitive pricing moves in the Jeuveau channel.

The frequency of these filings suggests material shifts in go-to-market strategy—potentially price reductions, expanded rebate tiers, or changes to Evolus Rewards eligibility. For practices, this represents an opportunity to renegotiate Jeuveau terms or test Evolus's competitive offer against your current Botox pricing. Jeuveau has steadily gained market share in the medspa channel, particularly among practices seeking to reduce per-unit toxin costs or diversify supplier risk. Evolus's aggressive positioning in the medspa segment (versus Allergan's broader aesthetic and pharmaceutical reach) makes it a credible alternative, especially for high-volume practices. Monitor Evolus investor relations for details on these filings and use them as leverage in your next supplier negotiation.

Source: original report ↗

Free weekly brief

Get the free weekly brief.

The week's most important moves in medical aesthetics — distilled to a two-minute read, free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Stay three moves ahead of every practice in your market.

Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.

Get the edge · $20/mo

Join the owners who run ahead of the industry. Cancel anytime, one click.

Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never be the last to know. Cancel anytime.
The twice-a-week intelligence brief Go Pro · $20/mo